Sarepta Therapeutics, Inc. [NASDAQ:SRPT]: Analyst Rating and Earnings
Professional stock traders oftentimes make sure they verify what some leading Wall Street voices have to say about a potential buy. Currently, in relation to Sarepta Therapeutics, Inc. [SRPT], the latest Wall Street average recommendation we can view is from the fiscal quarter that will be ending in the month of December. On average, stock market experts give SRPT an Outperform rating. Its stock price has been found in the range of 54.25 to 72.90. This is compared to its latest closing price of $127.00.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Sarepta Therapeutics, Inc. [SRPT] is sitting at 1.68. This is compared to 1 month ago, when its average rating was 1.65.
For the quarter ending in Sep-18 Sarepta Therapeutics, Inc. [SRPT] generated $0.08 billion in sales. That’s 0.97% lower than the average estimate of $0.08 billion as provided by Wall Street analysts. The three indicators above suggest that on the whole, this stock is not presenting an attractive investment option, as there are too many red flags that don’t point to a high-value ROI.
Keep on the lookout for this organization’s next scheduled financial results, which are expected to be made public on Thu 7 Mar (In 23 Days).
Fundamental Analysis of Sarepta Therapeutics, Inc. [SRPT]
Now let’s turn to look at profitability: with a current Operating Margin for Sarepta Therapeutics, Inc. [SRPT] sitting at -88.40 and its Gross Margin at +94.56, this company’s Net Margin is now -89.50%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is -17.37, and its Return on Invested Capital has reached -14.20%. Its Return on Equity is -9.00, and its Return on Assets is -5.85. These metrics suggest that this Sarepta Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Sarepta Therapeutics, Inc. [SRPT] has generated a Total Debt to Total Equity ratio of 54.62. Similarly, its Total Debt to Total Capital is 35.32, while its Total Debt to Total Assets stands at 32.96. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 53.84, and its Long-Term Debt to Total Capital is 34.82. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.
What about valuation? This company’s Enterprise Value to EBITDA is -65.09. The Enterprise Value to Sales for this firm is now 30.55, and its Total Debt to Enterprise Value stands at 0.16. Sarepta Therapeutics, Inc. [SRPT] has a Price to Book Ratio of 4.57.
Shifting the focus to workforce efficiency, Sarepta Therapeutics, Inc. [SRPT] earns $606,212 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 8.91 and its Total Asset Turnover is 0.18. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 12.96 and its Current Ratio is 13.91. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Let’s now turn our attention to trading performance: Sarepta Therapeutics, Inc. [SRPT] has 71.82M shares outstanding, amounting to a total market cap of $9.12B. Its stock price has been found in the range of 56.00 to 176.50. At its current price, it has moved by -25.63% from its 52-week high, and it has moved 134.38% from its 52-week low.
This stock’s Beta value is currently 2.10, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 53.70. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Sarepta Therapeutics, Inc. [SRPT] a Reliable Buy?
Sarepta Therapeutics, Inc. [SRPT] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.